Schulz T G, Neubert D, Davies D S, Edwards R J
Department of Clinical Pharmacology, Royal Postgraduate Medical School, London, UK.
Biochim Biophys Acta. 1996 Nov 14;1298(1):131-40. doi: 10.1016/s0167-4838(96)88917-5.
Cytochrome P-450 induction was investigated in the marmoset monkey, a non-human primate, using dioxins as inducing agents. Animals received a single subcutaneous dose of 1.6 nmol tetrachlorodibenzo-p-dioxin or tetrabromodibenzo-p-dioxin/kg body weight. Microsomal fractions were prepared from liver, lung and kidney, and homogenates were prepared from gut and adrenal glands. Anti-peptide antibodies which bind to CYP1A1, CYP1A2, CYP2B6 and CYP3A4 in human were used to identify related forms in the marmoset. The results indicate that CYP1A2 is constitutively expressed in liver, but not in lung, kidney, gut or adrenal gland and that CYP1A1 is not expressed in any of these tissues in untreated animals. Treatment with dioxin induced both CYP1A1 and CYP1A2 in liver, but only CYP1A1 in lung. No induction of CYP1A1 or CYP1A2 was found in kidney, small intestine or adrenal glands. Methoxy-, ethoxy-, pentoxy- and benzoyloxyresorufin O-dealkylases and high affinity phenacetin O-deethylase activities were induced in the liver, whereas ethoxycoumarin O-deethylase and aryl hydrocarbon hydroxylase activities were not affected by dioxin treatment. High-affinity phenacetin O-deethylase and CYP1A2 apoprotein were detected only in liver, consistent with this activity being specifically catalysed by CYP1A2. Furafylline was found to be a competitive inhibitor of methoxyresorufin O-demethylase activity with a Ki of 10 microM. In the lung the induction of CYP1A1 was accompanied by 15- and 23-fold increases in ethoxyresorufin O-deethylase and methoxyresorufin O-demethylase activities, respectively, suggesting that both activities are catalysed by CYP1A1. In contrast, there was no induction of aryl hydrocarbon hydroxylase activity in lung or liver showing that, unlike in many other species, marmoset CYP1A1 does not catalyse this reaction efficiently. The expression, distribution, induction and substrate specificities of marmoset monkey P-450 enzymes differ from the situation found in rodents and other species, demonstrating that caution has to be exercised when making cross-species extrapolations.
使用二噁英作为诱导剂,在非人类灵长类动物狨猴中研究细胞色素P - 450的诱导情况。动物接受皮下注射剂量为1.6 nmol四氯二苯并 - p - 二噁英或四溴二苯并 - p - 二噁英/千克体重。从肝脏、肺和肾脏制备微粒体部分,从肠道和肾上腺制备匀浆。使用与人类CYP1A1、CYP1A2、CYP2B6和CYP3A4结合的抗肽抗体来鉴定狨猴中的相关形式。结果表明,CYP1A2在肝脏中组成性表达,但在肺、肾脏、肠道或肾上腺中不表达,并且在未处理的动物中,CYP1A1在这些组织中均不表达。用二噁英处理诱导了肝脏中的CYP1A1和CYP1A2,但仅诱导了肺中的CYP1A1。在肾脏、小肠或肾上腺中未发现CYP1A1或CYP1A2的诱导。肝脏中诱导了甲氧基、乙氧基、戊氧基和苯甲酰氧基试卤灵O - 脱烷基酶以及高亲和力非那西丁O - 脱乙基酶活性,而乙氧基香豆素O - 脱乙基酶和芳烃羟化酶活性不受二噁英处理的影响。仅在肝脏中检测到高亲和力非那西丁O - 脱乙基酶和CYP1A2载脂蛋白,这与该活性由CYP1A2特异性催化一致。发现呋拉茶碱是甲氧基试卤灵O - 脱甲基酶活性的竞争性抑制剂,其Ki为1μM。在肺中,CYP1A1的诱导分别伴随着乙氧基试卤灵O - 脱乙基酶和甲氧基试卤灵O - 脱甲基酶活性增加15倍和23倍,表明这两种活性均由CYP1A1催化。相比之下,在肺或肝脏中未诱导芳烃羟化酶活性,这表明与许多其他物种不同,狨猴CYP1A1不能有效地催化该反应。狨猴P - 450酶的表达、分布、诱导和底物特异性与啮齿动物和其他物种的情况不同,这表明在进行跨物种推断时必须谨慎。